Department of Tissue Engineering & Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran; Department of Cell Engineering, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Biochem Biophys Res Commun. 2020 Apr 16;524(4):903-909. doi: 10.1016/j.bbrc.2020.02.009. Epub 2020 Feb 10.
The aim of this study was to investigate the cardiac repair effect of human bone marrow mesenchymal stromal cells-derived extracellular vesicles (MSC-EVs) after intramyocardial injection in free form or encapsulated within a self-assembling peptide hydrogel modified with SDKP motif, in a rat model of myocardial infarction (MI).
MSC-EVs were isolated by ultracentrifuge and characterized for physical parameters and surface proteins. Furthermore, cellular uptake and cardioprotective effects of MSC-EVs were evaluated in vitro using neonatal mouse cardiomyocytes (NMCMs). In vivo effects of MSC-EVs on cardiac repair were studied in rat MI model by comparing the vehicle group (injected with PBS), EV group (injected with MSC-EVs) and Gel + EV group (injected with MSC-EVs encapsulated in (RADA)-SDKP hydrogel) with respect to cardiac function and fibrotic area using echocardiography and Masson's trichrome staining, respectively. Histological sections were assessed by α-SMA and CD68 immunostaining to investigate the angiogenic and anti-inflammatory effects of the MSC-EVs.
We observed the uptake of MSC-EVs into NMCMs which led to NMCMs protection against HO-induced oxidative stress by substantial reduction of apoptosis. In myocardial infarcted rats, cardiac function was improved after myocardial injection of MSC-EVs alone or in conjunction with (RADA)-SDKP hydrogel. This functional restoration coincided with promotion of angiogenesis and decrement of fibrosis and inflammation.
These data demonstrated that MSC-EVs can be used alone as a potent therapeutic agent for improvement of myocardial infarction.
本研究旨在探讨心肌内注射游离形式或封装在具有 SDKP 基序的自组装肽水凝胶中的人骨髓间充质基质细胞衍生的细胞外囊泡(MSC-EVs)对心肌梗死(MI)大鼠模型的心脏修复作用。
通过超速离心分离 MSC-EVs,并对其物理参数和表面蛋白进行表征。此外,还通过使用新生鼠心肌细胞(NMCMs)在体外评估 MSC-EVs 的细胞摄取和心脏保护作用。通过比较 vehicle 组(注射 PBS)、EV 组(注射 MSC-EVs)和 Gel+EV 组(注射封装在(RADA)-SDKP 水凝胶中的 MSC-EVs),使用超声心动图和 Masson 三色染色分别评估 MSC-EVs 对心脏修复的体内作用,以评估心脏功能和纤维化面积。通过α-SMA 和 CD68 免疫染色评估 MSC-EVs 的血管生成和抗炎作用。
我们观察到 MSC-EVs 被 NMCMs 摄取,这导致 NMCMs 对 HO 诱导的氧化应激的保护作用,凋亡明显减少。在心肌梗死大鼠中,单独注射 MSC-EVs 或与(RADA)-SDKP 水凝胶联合注射均可改善心脏功能。这种功能恢复与促进血管生成和减少纤维化和炎症相一致。
这些数据表明,MSC-EVs 可单独用作改善心肌梗死的有效治疗剂。